RedHill Biopharma’s opaganib shows survival benefit in U.S. Army-funded study

RedHill Biopharma announced that novel, twice daily, oral opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day in a U.S. Army Medical Research Institute of Infectious Diseases in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease. The U.S. Army study tested three doses of opaganib against an inactive vehicle control arm. The in vivo study results showed a statistically significant survival increase in mean survival time of 11.2 days in the 150 mg/kg opaganib group compared to a mean survival time of 5.5 days in the inactive vehicle control group. A 30% mice survival was observed in the 150 mg/kg treated group compared to the vehicle control. Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe COVID-19 and was selected by the NIH Radiation and Nuclear Countermeasures Program for Acute Radiation Syndrome development.